Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Msci Inc (MSCI) vs Novavax Inc (NVAX) Price & Performance

Novavax IncTrade

Price performance (Past 24H)

Key statistics

Msci Inc vs Novavax Inc — how do they compare? Msci Inc trades at $559.94 (market cap $40.84B), while Novavax Inc trades at $7.92 (market cap $1.31B). The key difference: Msci Inc is far larger — about 31.2× Novavax Inc's market cap, and Msci Inc pays a 1.46% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.

MSCINVAX
Market Cap
$40.84B$1.31B
Sector
FinancialsHealth
52-Week High
$643.83$11.19
52-Week Low
$511.84$6.22
Enterprise Value
$47.00B$889.30M
Dividend Yield
1.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Msci Inc

MSCI trades at $562.00, down 0.19% in the last 24 hours, with a bearish technical signal from moving averages but oversold RSI hints at potential rebound. The company reported Q2 2026 EPS of $4.94, slightly missing the $4.99 estimate, yet revenue growth remains robust, with 2025 revenue at $3.13 billion and net income margin of 40.73%. Recent acquisitions like First Street and partnerships with UBS aim to expand its private markets analytics platform, supporting long-term growth.

Outlook is positive with a consensus price target of $728.14, implying 30% upside, driven by strong recurring revenue and high client retention. Risks include elevated debt levels of $4.51 billion and competitive pressures in financial data services. Analysts maintain 73% buy ratings, citing undervaluation relative to growth prospects, but investors should monitor execution on integration of recent acquisitions and interest rate impacts on financing costs.

Novavax Inc

Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.

The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.

Returns comparison

Trailing returns across standard periods

About Msci Inc

MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.

Read more on MSCI

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX